Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

ty and mechanism of action of APD811; the potential of APD811 and orally bioavailable, non-prostanoid prostacyclin receptor agonists in general; future study and evaluation of APD811; Arena's commitment to advance its pipeline; the therapeutic indication of Arena's most advanced drug candidate; and Arena's beliefs, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: there was a small safety margin from the no observed adverse effect level to significant adverse events in preclinical studies of APD811, and APD811 could have an unacceptable safety and efficacy profile in humans; the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
(Date:3/5/2015)... , March 5, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, today ... researchers to advisory roles. The panel of experts ... programs and efforts to advance the company pipeline ... They bring expertise in a range of areas ...
(Date:3/5/2015)... 5, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss year-end 2014 ... development programs for ThermoDox®, its proprietary heat-activated liposomal ... platforms, TheraPlas™ and TheraSilence™, in immunotherapy and RNA ... 12, 2015. To participate in the call, interested ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2
... May 13 NicOx S.A.,(Eurolist: COX) today announced ... in a series of planned clinical studies, in ... agreement to,develop new nitric oxide-donating antihypertensive agents using ... selected from,the companies, joint research program, of which ...
... study opens way for high-power permanent version of the glasses ... ... Innovative prism glasses can,significantly improve the vision and the daily lives ... in both eyes. The,peripheral prism glasses, which were invented by Dr. ...
Cached Medicine Technology:NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Prism Glasses Expand the View for Patients with Hemianopia 2Prism Glasses Expand the View for Patients with Hemianopia 3
(Date:3/6/2015)... Dr. Amy Reed, who together with her husband, ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in uterine ... the launch of their public health campaign. The couple told ... mother of six had recently undergone surgery to remove a ... Reed had been in remission for about a year after ...
(Date:3/6/2015)... Greenwood Village, CO (PRWEB) March 06, 2015 ... reducing infant mortality around the world is traveling to ... meet with survivors of their malnutrition program. , This ... the same region in Angola, demonstrating their commitment to ... five and under. The team will engage with the ...
(Date:3/6/2015)... 2015 Follow us on LinkedIn ... and crowns, abutments and dentures are used to provide ... teeth and missing teeth. The growth in the global ... by an aging global population, expanding number of edentulous ... the 65+ population being edentulous or completely toothless, there ...
(Date:3/6/2015)... 06, 2015 US Sports Football Camps ... camps – two non-contact specialty camps and one contact ... Perfect Performance Training, located at Bowie State University and ... position specific skills, speed and strength of football athletes. ... University with Marvin Graves, former quarterback in the Canadian ...
(Date:3/6/2015)... 2015 Since Medicare began paying for ... has been an overwhelming demand from providers for straightforward ... CCM program. The Centers for Medicare & Medicaid ... , PYA’s updated white paper—“ Providing and Billing Medicare ... a detailed, yet practical “how to” manual for providers ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Aging Population & Emphasis on Dental Care Drives the Dental Prosthetic & Implant Consumables Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Aging Population & Emphasis on Dental Care Drives the Dental Prosthetic & Implant Consumables Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2
... , , Medtronic Featured as Official ... The American Association of Heart Failure Nurses (AAHFN) is ... February 8-14 .   , The purpose of Heart Failure Awareness ... common and debilitating condition.  AAHFN will achieve this goal through the ...
... but effective treatment, experts say , FRIDAY, Feb. 5 ... can be killed by a type of bacteria that ... maggots to disinfect wounds (maggot debridement therapy) is standard ... dead tissue and ingest bacteria that are killed in ...
... responsible for ,pending epidemic, researchers say , FRIDAY, Feb. ... patients but can cause work-related injuries in surgeons, suggests ... Medicine researchers found that 87 percent of laparoscopic surgeons ... physical symptoms or discomfort. , "We face a pending ...
... NEW YORK , Feb. 5 Hospital for ... today announced its support of the Arthritis Foundation and Ad ... raise awareness of osteoarthritis, increase public health education and support ... our extensive clinical and research resources on raising awareness of ...
... , , BEIJING, CHINA , Feb. 5 ... attention to a certain previously released news announcements namely January 7 ... January 12,2010 , and January 22, 2010 . , These ... these events are now starting to crystallize and are beginning to transform ...
... more likely to misuse prescribed drugs, suffer flareups ... patients who use herbal remedies experience increased symptoms and ... Researchers followed 326 asthma patients for 33 months. Of ... and used prescribed inhaled corticosteroids (ICS) less often than ...
Cached Medicine News:Health News:AAHFN Promotes Heart Failure Awareness Week Through Webinar 2Health News:Wound-Healing Maggots Succumb to Deadly Bacteria 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 3Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Herbals Not the Answer for Asthma, Study Shows 2
... growing portfolio of OxiMax® monitors, the ... compact, affordable bedside monitor. Equipped with ... it offers reliable operation during challenging ... the complete family of innovative OxiMax ...
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery....
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
... Model 130 has expanded memory capabilities for overnight ... to retain oxygen saturation and pulse rate data, ... best suit your needs:, ,1. The Model ... information for a single patient, making the device ...
Medicine Products: